Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NL 201

Next Previous
Search
Drug Profile

NL 201

Alternative Names: mIL-11; Mutein interleukin-11; NL 002; NL-201; VM-501

Latest Information Update: 28 Aug 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Northland Biotech
  • Developer Beijing Northland Biotech; Helixmith
  • Class Chemoprotectants; Interleukins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Haematopoiesis stimulants; Interleukin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Thrombocytopenia

Highest Development Phases

  • Phase III Thrombocytopenia
  • No development reported Blood coagulation disorders

Most Recent Events

  • 28 Aug 2021 No recent reports of development identified for preclinical development in Blood-coagulation-disorders in China (SC, Injection)
  • 28 Aug 2019 NL 201 is still in phase III trials for Thrombocytopenia in China (Viromed pipeline, August 2019)
  • 21 Jun 2016 Preclinical trials in Coagulation disorders in China (SC) before June 2016

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top